Clinical Practice Guidelines and Consensus Statements in Oncology – An Assessment of Their Methodological Quality

作者: Carmel Jacobs , Ian D. Graham , Julie Makarski , Michaël Chassé , Dean Fergusson

DOI: 10.1371/JOURNAL.PONE.0110469

关键词:

摘要: Background Consensus statements and clinical practice guidelines are widely available for enhancing the care of cancer patients. Despite subtle differences in their definition purpose, these terms often used interchangeably. We systematically assessed methodological quality consensus published three commonly read, geographically diverse, cancer-specific journals. Methods Consensus between January 2005 September 2013 Current Oncology, European Journal Cancer Clinical Oncology were evaluated. Each publication was using Appraisal Guidelines Research Evaluation II (AGREE II) rigour development editorial independence domains. For assessment transparency document development, 7 additional items taken from Institute Medicine’s standards authors guidance documents. Methods Medicine's documents. Findings Thirty-four 67 The score over journals 32% lower than that guidelines. 15% One journal scored consistently others both No adhered to all related development. journal’s endorsed a product made by sponsoring pharmaceutical company 64% cases. Conclusion Guidance documents an essential part oncology should be subjected rigorous validated process. had AGREE II. At minimum, ensure adhere criteria. Journals consider explicitly requiring declare sponsorship identify sponsor’s enhance transparency.

参考文章(125)
Michelle Mancher, Dianne Miller Wolman, Sheldon Greenfield, Robin Graham, Earl Steinberg, Clinical Practice Guidelines We Can Trust ,(2013)
Christopher Smith, Alemtuzumab in chronic lymphocytic leukemia. Current Oncology. ,vol. 14, pp. 96- 109 ,(2007) , 10.3747/CO.2007.118
S. H Woolf, R. Grol, A. Hutchinson, M. Eccles, J. Grimshaw, Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. ,vol. 318, pp. 527- 530 ,(1999) , 10.1136/BMJ.318.7182.527
D Jonker, RB Rumble, J Maroun, Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care, Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer Current Oncology. ,vol. 13, pp. 173- 184 ,(2006) , 10.3747/CO.V13I5.99
L. Sideris, S. Hanna, D. Rayson, L. Siu, R. Reid, P. Poitras, A. Roy, A. Shah, L. Kvols, E. Chen, R. Wong, J. Rivera, J. Maroun, G. Bjarnason, C. Germond, W. Kocha, Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Current Oncology. ,vol. 13, pp. 67- 76 ,(2006) , 10.3747/CO.V13I2.84
T Petrella, I Quirt, S Verma, AE Haynes, M Charette, K Bak, members of the Melanoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care, Single-agent interleukin-2 in the treatment of metastatic melanoma. Current Oncology. ,vol. 14, pp. 21- 26 ,(2007) , 10.3747/CO.2007.97
K Imrie, A Stevens, C A Smith, D Reece, Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline. Current Oncology. ,vol. 13, pp. 160- 172 ,(2006) , 10.3747/CO.V13I5.106
I Quirbt, S Verma, T Petrella, K Bak, M Charette, members of the Melanoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care, Temozolomide for the treatment of metastatic melanoma. Current Oncology. ,vol. 14, pp. 27- 33 ,(2007) , 10.3747/CO.2007.98